Market PotentialTH103 has the potential to offer better outcomes and longer treatment intervals than current anti-VEGF therapies for the treatment of retinal vascular diseases, which represents a roughly $15 billion market globally.
Preclinical ResultsTH103 has shown greater anti-VEGF potency and significantly longer durability than Eylea in head-to-head preclinical studies.
Product DevelopmentKalaris is developing TH103, an anti-VEGF fusion protein designed to offer potentially longer-lasting and increased anti-VEGF activity than current treatments.